๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase

โœ Scribed by H. Y. Pan

Publisher
Springer
Year
1991
Tongue
English
Weight
445 KB
Volume
40
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Therapeutic efficacy of the HMG-CoA-redu
Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II
โœ H. Saxenhofer; P. Weidmann; W. F. Riesen; C. Beretta-Piccoli; C. Fragiacomo; R. ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› Springer ๐ŸŒ English โš– 533 KB

The efficacy and safety of the HMG-CoA-reductase inhibitor pravastatin was assessed in a double-blind, placebo controlled study. Thirty patients (51 y) with hyperlipoproteinaemia Type IIa (N = 22) or IIb (N = 8) received for 16 weeks either pravastatin 5 mg b.d. for 8 weeks followed by 10 mg b.d. fo

Synthesis of a novel HMG-COA reductase i
Synthesis of a novel HMG-COA reductase inhibitor
โœ E. Baader; W. Bartmann; G. Beck; A. Bergmann; H. Jendralla; K. Kesseler; G. Wess ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Elsevier Science ๐ŸŒ French โš– 120 KB

The synthesis of a new 3-hydroxy-3-methylglutaryl coenzyme A reduc-----tase inhibitor starting from 4,4' -difluorobenzophenone is described. Mevinolin 1 and its congeners are potent inhibitors of 3-hydroxy-3-methyl-